Dr. Aditya Bardia reviews findings from the phase 3 lidERA trial evaluating oral SERD geridestrant in stage I–III ER+/HER2- breast cancer. The study showed improved invasive disease-free and distant recurrence outcomes compared to standard endocrine therapy, along with a safety profile consistent with prior experience.
